The Wolff-Parkinson-White syndrome can be complicated by atrial fibrillation that may increase morbidity and mortality. Different pharmacologic therapy, inlcuding class IA, IC, and III agents, has been used in such cases with variable success. We now use less pharmacologic intervention with development of an electrode catheter ablation for accessory pathways. However, antiarrhythmic agents are still being used, especially when an electrode catheter ablation is unavailable or if a patient refuses such a procedure. Therefore, it is prudent that one understands each antiarrhythmic agent's electrophmacologic properties as well as its potential proarrhythmic effect in order to accurately assess each drug's risk-benefit ratio. We present a case that illustrates electropharmacologic properties of quinidine. flecainide, sotalol, and amiodarone on various cardiac tissues, as well as possible proarrhythmic effect of flecainide on a structurally normal heart.
Josephson ME, Kastor JA. Supraventricular tachycardia: Mechanisms and management. Ann Intern Med187:346, 1977
3.
Wellens HJJ, Durrer D. Wolff-Parkinson-White syndrome and atrial fibrillation. Am J Cardiol344:777, 1974
4.
Schluter M. Geiger M, Siebels J, Duckeck W, Kuck KH.Catheter ablation using radiofrequency current to cure symptomatic patients with tachyarrhythmias related to an accessory atrioventricular pathway. Circulation84:1644, 1991
5.
Sharma AD, Klein GJ, Guiraudor GM, Milstein S. Atrial fibrillation in patients with Wolff-Parkinson-White syndrome: Incidence after surgical ablation of the accessory pathyway. Circulation72:161, 1985
6.
Feld GK, Nademanee K, Stevenson W, Weiss J, Klitzner T, Singh BN. Clinical and electrophysiologic effects of amiodarone in patients with atrial fibrillation complicating the Wolff-Parkinson-White Syndrome. Am Heart J115:102, 1988
7.
Feld GK, Nademanee K, Weiss J, Stevenson WV, Singh BN. Electrophysiologic basis for the suppression by amiodarone of orthodromic supraventricular tachycardia complicating preexcitation syndromes. J Am Coll Cardiol3:1298, 1984
8.
Podrid PJ, Lown B. Amiodarone in symptomatic sustained refractory atrial and ventricular tachyarrhythmias. Am Heart J101:374, 1981
9.
Rowland E, Krikler DM. Electrophysiologic assessment of amiodarone in treatment of resistant supraventricular arrhythmias. Am J Cardiol44:82, 1980
10.
Chamberlain DA, Clark ANG. Atrial fibrillation complicating Wolff-Parkinson-White syndrome treated with amiodarone. B M J60:1519, 1977
11.
Morady F, DiCarlo LA, Krol RB, Baerman JM, DeBuitler M. Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. J Am Coll Cardiol7:145, 1986
12.
Yabek S, Kato R, Singh BN. Effects of amiodarone and its metabolite, desethylmiodarone, on the electrophysiologic properties of isolated cardiac muscle. J Cardiovasc Pharmacol8:197, 1976
13.
Kappenberger LJ, Fromer MA, Steinbrunn W, Shenasa M. Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. Am J Cardiol54:33, 1984
14.
Kappenberger LJ, Fromer MA, Shenasa M, Gloor HO. Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome. Clin Cardiol8:321, 1985
15.
Manolis AS, Salem DN, Estes III NAM. Electrophysiologic effects, efficacy and tolerance of class Ic antiarrhythmic agents in Wolff-Parkinson-White syndrome. Am J Cardiol63:746, 1989
16.
Nathan AW, Camm AJ, Bexton RS, Hellestrand KJ. Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias. Clin Cardiol10:317, 1987
17.
Chouty F, Coumel P. Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. Am J Cardiol62:335D, 1988
18.
Anderson JL, Jolivette DM, Fredell PA. Summary of efficacy and safety of flecainide for supraventricular arrhythmias. Am J Cardiol62:62D, 1988
19.
Hellestrand KJ, Bexton RS, Nathan AW, Spurrell RAJ, Camm AJ. The acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J48:140, 1982
20.
Hellestrand KJ. Nathan AW, Bexton RS, Spurrell RAJ, Camm AJ.Cardiac electrophysiologic effects of flecainide acetate for paroxysmal reentrant junctional tachycardias. Am J Cardiol51:770, 1983
21.
Wang Z. Pelletier LC, Talajic M, Nattel S.Effects of flecainide and quinidine on human atrial action potentials: Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. Circulation1982:274, 1990
22.
Special report:Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med321:406, 1989
23.
Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med111:107, 1989
24.
Morganroth J, Horowitz LN. Flecainide: Its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol53:89B, 1984
25.
Feld GK, Chen PS, Nicod P, Fleck P, Meyer D. Possible atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol66:378, 1990
26.
Marcus FI. The hazards of using type IC antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation. Am J Cardiol66:366, 1990
27.
Sihm I, Hansen A, Rasmussen J, Pedersen AK, Thygesen K. Flecainide acetate in atrial flutter and fibrillation: The arrhythmogenic effects. Eur Heart J11:145, 1990
28.
Nathan AW, Hellestrand KJ, Bexton RS, Banium SO, Spurrell RAJ, Camm AJ. Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate. Am Heart J107:222, 1984
29.
Herre JM, Titus C, Oeff M, Eldar M, Eldar MR, Griffin JC, Scheinman MM. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. Ann Intern Med113:671, 1990
30.
Pritchett ELC, Wilkinson WE. Mortality in patients treated with flecainide and encainide for supnventricular arrhythmias. Am J Cardiol67:976, 1991
31.
Rosen MR. Wit AL.Arrhythmogenic actions of antiarrhythmic drugs. Am J Cardiol59:10E, 1987
32.
Hondeghem LM. Snyders DJ.Class III antiarrhythmic agents have a lot of potential but a long way to go. Circulation81:686, 1990
33.
Singh BN, Nademanee K. Sotalol: A beta blocker with unique antiarrhythmic properties. Am Heart J114:121, 1987
34.
Touboul P, Atallah G, Kirkorian G, Lamaud M, Moleur P. Clinical electrophysiology of intravenous sotalol, a beta-blocking drug with class III antiarrhythmic properties. Am Heart J107:888, 1984
35.
Nathan AW, Hellestrand KJ, Bexton RS, Ward DE, Spurrell RAJ, Camm AJ. Electrophysiological effects of sotalol: Just another beta blocker?Br Heart J47:515, 1982
36.
Singh BN. Historical development of the concept of controlling carrdiac arrhythmias by lengthening repolarization: Particular reference to sotalol. Am J Cardiol65:3A, 1990
37.
Nademanee K, Singh BN. Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: Comparison with other antiarrhythmic agents. Am J Cardiol65:53A, 1990
38.
Strauss HC, Bigger JT, Hoffman BE. Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog & rabbit cardiac tissue. Circ Res26:661, 1970
39.
Singh BN, Vaughan Williams EM. A third class of antiarrhythmic action: Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of JM 1999 and AH 3474. Br J Pharmacol39:675, 1970
40.
Edvardsson N, Hirsch I, Emanuelsson H, Ponka J, Olsson SB. Sotalol induced delayed ventricular repolarization in man. Eur Heart J1:335, 1980
41.
Anderson KP, Walker R, Dustman T, Lux RL, Ershler PR, Kales RE, Urie PM. Rate-related electrophysiologic effects of long-term administration of amiodarone on canine ventricular myocardium in vivo. Circulation79:948, 1989
42.
Singh BN, Ahmed R. Class III antiarrhythmic drugs. Curr Opin Cardiol19:12, 1993
43.
Anastasiou-Nana MI, Anderson JL, Stewart JR, Cresey BJ, Yanowitz FG, Lutz JR, Johnson TA.Occurrence of exercise induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: A probable proarrhythmic effect. Am Heart J113:1071, 1987
